Authors
Shufeng Ma, Changyuan Kang, Xixian Liu, Lichao Yang, Mengyi Li, Yuting Ye, Jianfang Zhang, Yingjun Li, Guanghui Jin, Yang Liu, Xiaohong Chen, Kexin Wang, Zifeng Yang
Published in
Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e77883. Sep 27, 2026. Epub Sep 27, 2026.
Abstract
Influenza A virus (IAV) commandeers host transcriptional machinery to replicate, but mechanisms remain elusive. CRISPR screen identifies PARP1 as a proviral factor that binds viral NS1. ATAC‑seq reveals IAV drives PARP1‑dependent chromatin remodeling at promoter‑proximal regions (-100 to +300 bp), linking PARP1 to viral RNA synthesis. Mechanistically, NS1 engages PARP1's helical domain (HD), which alone forms large, irregular condensates with low fluidity, acting as a built‑in rheostat. HD deletion confers high droplet mobility, whereas NS1 binding locks PARP1 into a hyper‑condensed, gel‑like state. This phase transition traps Pol II in prolonged pause by enriching pausing factors (SPT5‑PLD, NELFA, NELFE) and excluding release factors (SPT5‑PRD, AFF4). The paused environment is hijacked for efficient cap‑snatching and viral RNA synthesis. This proviral activity is independent of PARP1's polymerase activity, revealing a non‑canonical mechanism that complements recent reports of PARP1‑mediated antiviral ADP‑ribosylation. Targeting this phase transition, we identify tectochrysin (TEC) and isoferulic acid (IFA), which restore fluidity, reverse pausing, and suppress IAV in mice and lung organoids without toxicity. Our work establishes that NS1 coopts PARP1 phase separation via the HD rheostat to prolong transcriptional pausing, introducing 'phase transition correction' as an antiviral paradigm.
PMID:
42801698
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 21
- Comments 0